|
As R&D productivity declines and the age of blockbuster medicines reaches an end, the pharmaceutical industry is looking at ways to extend the profitable life of its products up to and beyond patent expiry. |
07-Jan-2008 - A recent report has detailed the challenges facing the pharma industry as the generic flood gates open, with the constant advice to start planning early still apparently not heeded by a bewildering number of firms.
02-Nov-2007 - With IMS Health's annual forecast for the pharma industry predicting slower approvals, more black box warnings and the continuation of the 'wave of genericization,' the shift by pharma firms to refocus and reinvent themselves will need to move on apace in order to secure their position in a changing market.
16-Oct-2007 - The US is woefully lagging behind the EU when it comes to approving biosimilars, a new report says.
31-Jul-2007 - European pharmaceutical and medical authorities have announced their satisfaction on the progress being made with the European Risk Management Strategy (ERMS) following a meeting earlier this month.
16-May-2007 - There are some areas of the European approval system for biosimilars that still need to be clarified, a panel of industry experts said during BIO 2007.
22-Feb-2007 - A report to be published next week predicts that US and EU pharmas will lose up to $100bn in revenues over the next five years as generic products take advantage of major branded products losing patent protection.